Kelly WK - Search Results

1

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. Halabi S, et al. Among authors: kelly wk. J Clin Oncol. 2023 May 20;41(15):2736-2746. doi: 10.1200/JCO.22.02661. Epub 2023 Apr 11. J Clin Oncol. 2023. PMID: 37040594 Free PMC article.

2

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications.

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. Ghossein RA, et al. Among authors: kelly wk. J Clin Oncol. 1995 May;13(5):1195-200. doi: 10.1200/JCO.1995.13.5.1195. J Clin Oncol. 1995. PMID: 7537803

3

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, Scher HI. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2208-13. doi: 10.1200/JCO.1995.13.9.2208. J Clin Oncol. 1995. PMID: 7545218 Clinical Trial.

4

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Pfister D, Curley T, Leibertz C, Cohen L, Vlamis V, Dnistrian A, Schwartz M. Kelly WK, et al. J Clin Oncol. 1995 Sep;13(9):2214-22. doi: 10.1200/JCO.1995.13.9.2214. J Clin Oncol. 1995. PMID: 7666079 Clinical Trial.

5

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Kelly WK, et al. J Clin Oncol. 1993 Apr;11(4):607-15. doi: 10.1200/JCO.1993.11.4.607. J Clin Oncol. 1993. PMID: 7683043

6

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.

Scher HI, Kelly WK. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 1993 Aug;11(8):1566-72. doi: 10.1200/JCO.1993.11.8.1566. J Clin Oncol. 1993. PMID: 7687666

7

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. McCaffrey JA, et al. Among authors: kelly wk. J Clin Oncol. 1997 May;15(5):1853-7. doi: 10.1200/JCO.1997.15.5.1853. J Clin Oncol. 1997. PMID: 9164195 Clinical Trial.

8

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.

McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. McCaffrey JA, et al. Among authors: kelly wk. J Clin Oncol. 1997 Jun;15(6):2449-55. doi: 10.1200/JCO.1997.15.6.2449. J Clin Oncol. 1997. PMID: 9196161 Clinical Trial.

9

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Scher HI, et al. Among authors: kelly wk. J Clin Oncol. 1997 Aug;15(8):2928-38. doi: 10.1200/JCO.1997.15.8.2928. J Clin Oncol. 1997. PMID: 9256137

10

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI. Sabbatini P, et al. Among authors: kelly wk. J Clin Oncol. 1999 Mar;17(3):948-57. doi: 10.1200/JCO.1999.17.3.948. J Clin Oncol. 1999. PMID: 10071289 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

234 results

Search Page

Filters